Share This Article:

Effect of Factor V Leiden on Thrombosis in Childhood Leukemia

Abstract Full-Text HTML Download Download as PDF (Size:133KB) PP. 100-103
DOI: 10.4236/ojbd.2013.33020    3,724 Downloads   5,207 Views   Citations


Thromboembolism is an important complication in children undergoing therapy for ALL as it has the potential to impact adversely on both their survival and quality of life. The incidence of thrombosis in children with ALL varies between 1.1% and 36.7% and the actual mean is 3.2%. The aim of our study is to review the available reported data on the effect of FVL on thrombotic risk in pediatric patients with acute leukemia.

Conflicts of Interest

The authors declare no conflicts of interest.

Cite this paper

D. Akın and N. Akar, "Effect of Factor V Leiden on Thrombosis in Childhood Leukemia," Open Journal of Blood Diseases, Vol. 3 No. 3, 2013, pp. 100-103. doi: 10.4236/ojbd.2013.33020.


[1] V. Caruso, L. Lacoviello, A. D. Castelnuovo, S. Storti, G. Mariani, G. D. Gaetano and M. D. Donati, “Thrombotic Complications in Childhood Acute Lymphoblastic Leukemia: A Meta-Analysis of 17 Prospective Studies Comprising 1752 Pediatric Patients,” Blood, Vol. 108, No. 7, 2006, pp. 2216-2222.
[2] L. G. Mitchell, M. Andrew and K. Hanna, “A Prospective Cohort Study Determining the Prevalence of Thrombotic Events in Children with Acute Lymphoblastic Leukemia and a Central Venous Line Who Are Treated with L-Asparaginase: Results of the Prophylactic Antithrombin Replacement in Kids with Acute Lymphoblastic Leukemia Treated with Asparaginase (PARKAA) Study,” Cancer, Vol. 97, No. 2, 2003, pp. 508-516.
[3] N. Santoro, P. Giordano and G. C. Del Vecchio, “Ischemic Stroke in Children Treated for Acute Lymphoblastic Leukemia: A Retrospective Study,” Journal of Pediatric Hematology/Oncology, Vol. 27, 2005, pp. 153-157.
[4] T. Celkan, H. Apak, A. Ozkan, V. Guven, T. Erkan, F. Cullu, L. Yüksel and I. Yildiz, “The Etiology of Thromboembolism in Hospitalized Children,” Turkish Pediatric Archive, Vol. 39, 2004, pp. 65-70.
[5] A. C. Homans, M. E. Rybak, R. L. Baglini, C. Tiarks, M. E. Steiner and E. N. Forman, “Effect of L-Asparaginase Administration on Coagulation and Platelet Function in Children with Leukemia,” Journal of Clinical Oncology, Vol. 5, 1987, p. 811.
[6] N. Semeraro, P. Montemurro, P. Giordano, F. Schettini, N. Santoro, D. De Mattia, D. Giordano, M. Conese and M. Collucci, “Unbalanced Coagulation-Fibrinolysis Potential during L-Asparaginase Therapy in Children with Acute Lymphoblastic Leukemia,” Thromb Haemost, Vol. 64, 1990, p. 38.
[7] D. E. Sutherland, I. C. Weitz and H. A. Liebman, “Thromboembolic Complications of Cancer: Epidemiology, Pathogenesis, Diagnosis, and Treatment,” American Journal of Hematology, Vol. 72, No. 1, 2003, pp. 43-52.
[8] U. Nowak-Gottl, R. Junker, W. Kreuz, A. V. Eckardstein, A. Kosh, N. Nohe, R. Schobess and S. Ehrenforth, “Risk of Recurrent Venous Thrombosis in Children with Combined Prothrombotic Risk Factors,” Blood, Vol. 97, No. 4, 2001, pp. 858-862.
[9] N. Akar, “Factor V 1691 G-A Mutation Distribution in a Healthy Turkish Population,” Turkish Journal of Hematology, Vol. 26, 2009, pp. 9-11.
[10] N. Akar, M. Misiroglu and E. Akar, “Prothrombin Gene 20210 G-A Mutation in the Turkish Population,” American Journal of Hematology, Vol. 58, No. 3, 1998, p. 249.<249::AID-AJH20>3.0.CO;2-3
[11] R. M. Bertina, B. P. Koeleman and T. Koster, “Mutation in Blood Coagulation Factor V Associated with Resistance to Activated Protein C,” Nature, Vol. 369, 1994, pp. 64-67.
[12] A. Redaelli, B. L. Laskin, J. M. Stephens, M. F. Botteman and C. L. Pashos, “A Systematic Literature Review of the Clinical and Epidemiological Burden of Acute Lymphoblastic Leukaemia (ALL),” European Journal of Cancer Care, Vol. 14, 2005, pp. 53-62.
[13] U. Nowak-Gottl, C. Wermes, R. Junker, H. G. Koch, R. Schobess, G. Fleischhack, D. Schwabe and S. Ehrenforth, “Prospective Evaluation of the Thrombotic Risk in Children with Acute Lymphoblastic Leukemia Carrying the MTHFR TT 677 Genotype, the Prothrombin G20210A Variant, and Further Prothrombotic Risk Factors,” Blood, Vol. 93, 1999, pp. 1595-1599.
[14] S. Ziegler, W. R. Sperr and P. Knobl, “Symptomatic Venous Thromboembolism in Acute Leukemia: Incidence, Risk Factors, and Impact on Prognosis,” Thrombosis Research, Vol. 115, No. 1-2, 2005, pp. 59-64.
[15] B. Falanga, “Hemorrhage and Thrombosis in Acute Leukemia,” Haematologica Reports, Vol. 1, No. 9, 2005, pp. 48-51.
[16] S. Sivaslioglu, T. Gursel, U. Kocak and Z. Kaya, “The Risk Factors for Thrombosis in Children with Acute Lymphoblastic Leukemia,” Clinical and Applied Thrombosis/Hemostasis, 2013, pp. 278-281.
[17] D. F. Akin, K. Sipahi, T. Kayaalp, Y. Egin, S. Tasdelen, A. E. Kurekci and N. Akar, “Factor V Leiden and Prothrombin 20210A Mutations among Turkish Pediatric Leukemia Patients,” Leukemia Research and Treatment, 2012, pp. 345-349.
[18] M. Sifontes, R. Nuss, S. P. Hunger, S. Wilimas and L. Jacobsan, “The Factor V Leiden Mutation in Children with Cancer and Thrombosis,” British Journal of Haematology, Vol. 96, No. 3, 1997, pp. 484-489.
[19] H. G. Ku, R. H. White, H. K. Chew, D. J. Harvey, H. Zhou and T. Wun, “Venous Thromboembolism in Patients with Acute Leukemia: Incidence, Risk Factors, and Effect on Survival,” Blood, 2009, pp. 113-117.
[20] R. Elhasid, N. Lanir and R. Sharon, “Prophylactic Therapy with Enoxaparin during L-Asparaginase Treatment in Children with Acute Lymphoblastic Leukemia,” Blood Coagulation & Fibrinolysis, Vol. 12, No. , 2001, pp. 367-370.
[21] Z. Rahimi, Akramipour, H. Mozafari, K. Yari, M. R. Golpaygani and A. S. Ahmadi, “Association of Factor V Leiden Mutation with Pediatric Acute lymphoblastic Leukemia in Kermanshah Province,” Journal of Hematology-Oncology and Stem Cell Research, Vol. 6, 2012, p. 10.
[22] Y. A. Torun, T. Patiroglu, M. A. Ozdemir, Y. Ozkul, A. Ekici and M. Karakukcu, “Inherited Prothrombotic Risk Factors in Turkish Children with Acute Lymphoblastic Leukemia: Significance of Concomitant Genetic Mutation,” Clinical and Applied Thrombosis/Hemostasis, Vol. 18, No. 2, 2012, pp. 218-221.
[23] H. M. Otterson, J. Mathijssen, H. Ten Cate, M. Soesan, M. Inghels, D. J. Richel and M. H. Prins, “Symptomatic Venous Thromboembolism in Cancer Patients Treated with Chemotherapy: An Underestimated Phenomenon,” Archives of Internal Medicine, Vol. 164, No. 2, 2004, pp. 190-194.
[24] E. Ramacciotti, N. Wolosker, P. Puech-Leao, E. A. Zeratti, P. R. Gusson, A. del Giglio and R. F. Franco, “Prevalence of Factor V Leiden, FII G20210A, FXIII Val34Leu and MTHFR C677T Polymorphisms in Cancer Patients with and without Venous Thrombosis,” Thrombosis Research, Vol. 109, No. 4, 2003, pp. 171-174.
[25] N. U. Gottl, G. Kenet and L. G. Mitchell, “Thrombosis in Childhood Acute Lymphoblastic Leukaemia: Epidemiology, Etiology, Diagnosis, Prevention and Treatment,” Best Practice & Research Clinical Haematology, Vol. 22, No. 1, 2009, pp. 103-114.

comments powered by Disqus

Copyright © 2018 by authors and Scientific Research Publishing Inc.

Creative Commons License

This work and the related PDF file are licensed under a Creative Commons Attribution 4.0 International License.